All posts by Dr Derek Jellinek
Senior Analyst
Sectors Covered: Healthcare
By Dr Derek Jellinek
04 May 2021, 5:00 PM
Derek Jellinek, Senior Analyst at Morgans, discusses Sonic Healthcare (ASX:SHL), an addition to our Morgans Best Ideas (May 2021).
Read more...
By Dr Derek Jellinek
28 April 2021, 4:50 PM
Ongoing elevated demand for PPE and product supply on track to meet that
demand saw the company provide a favourable trading update and upgrade
guidance, again.
Read more...
By Dr Derek Jellinek
15 March 2021, 3:10 PM
While we make no changes to our estimates or price target, we believe CSL share weakness offers an opportunity to buy a high-quality business at a discount.
Read more...
By Dr Derek Jellinek
18 February 2021, 4:30 PM
In CSL Ltd's 1H21 results, Seqirus was the standout on pandemic driven demand for influenza vaccines, while Behring gained from Albumin sales and cost-outs, but Ig growth was modest and Specialty /Haemophilia fairly flat.
Read more...
By Dr Derek Jellinek
17 February 2021, 11:20 AM
Our valuation rises, with a TSR (total shareholder return) of >10%, we move to an Add recommendation.
Read more...
By Dr Derek Jellinek
10 February 2021, 9:00 AM
We highlight our expectations for the following ahead of Reporting Season First Half 2021: ResMed, Sonic Healthcare, Virtus Health, Monash IVF, Volpara, Pro Medicus, and Mach7 Technologies. Watch now.
Read more...
By Dr Derek Jellinek
29 October 2020, 12:00 AM
In this note, we assess the impact across key healthcare segments, highlighting ASX and international listed companies as well as ETFs which allow exposure to these themes.
Read more...
By Dr Derek Jellinek
13 October 2020, 4:45 PM
Morgans Senior Analyst, Dr. Derek Jellinek, provides a comprehensive update on the Covid-19 Vaccine. Additionally, Derek breaks down the key stakeholders within the race, and how they are currently positioned.
Read more...
By Dr Derek Jellinek
20 August 2020, 4:00 PM
We adjust FY21-22 estimates and roll forward our valuation multiples, with our price target increasing.
Read more...
By Dr Derek Jellinek
19 August 2020, 11:00 AM
FY20 results were negatively impacted by COVID-19 deferral of elective surgeries, with sales declining across all divisions, margins contracting, underlying profit falling by double-digits and the dividend remaining suspended. As a result, we have asjusted our FY21-22 expectations.
Read more...